In vivo assessment of the combination of the JAK1 selective inhibitor itacitinib with first- and second-generation EGFR inhibitors in models of non-small cell lung cancer

被引：2
|
作者：
Stubbs, Matthew C. [1 ]
Wen, Xiaoming [1 ]
Xue, Chu-Biao [1 ]
Huang, Taisheng [1 ]
Yao, Wenqing [1 ]
Metcalf, Brian [1 ]
Huber, Reid [1 ]
Scherle, Peggy [1 ]
Ruggeri, Bruce [1 ]
机构：
[1] Incyte Corp, Wilmington, DE USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2938
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2938
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
    Li, Yufeng
    Mao, Tianyu
    Wang, Jing
    Zheng, Hongrui
    Hu, Ziyi
    Cao, Pingping
    Yang, Suisui
    Zhu, Lingyun
    Guo, Shunyao
    Zhao, Xinfei
    Tian, Yue
    Shen, Hua
    Lin, Fan
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [42] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
    Yufeng Li
    Tianyu Mao
    Jing Wang
    Hongrui Zheng
    Ziyi Hu
    Pingping Cao
    Suisui Yang
    Lingyun Zhu
    Shunyao Guo
    Xinfei Zhao
    Yue Tian
    Hua Shen
    Fan Lin
    Cell Communication and Signaling, 21
  • [43] Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece
    Cheng, Mindy
    Akalestos, Athanasios
    Scudder, Sidney
    DIAGNOSTICS, 2020, 10 (06)
  • [44] Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines
    Jose da Silva-Oliveira, Renato
    Faria Gomes, Izabela Natalia
    da Silva, Luciane Sussuchi
    Lengert, Andre van Helvoort
    Laus, Ana Carolina
    Melendez, Matias Eliseo
    Munari, Carla Carolina
    Cury, Fernanda de Paula
    Longato, Giovanna Barbarini
    Reis, Rui Manuel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [45] The reversible resistance mechanisms of second generation EGFR-TKI, Dacomitinib, in non-small cell lung cancer
    Haga, Yuya
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2023, 114 : 1071 - 1071
  • [46] Gefitinib first or gefitinib second -: Is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jaenne, Pasi A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) : 783 - 785
  • [47] Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1173 - S1176
  • [48] Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors
    Spagnuolo, Alessia
    Maione, Paolo
    Gridelli, Cesare
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (03) : 231 - 241
  • [49] FIRST GENERATION EGFR- TKIS COMPARISON IN NON-SMALL CELL LUNG CANCER PATIENTS HARBOURING SENSITIVE EGFR MUTATIONS
    Chang, Chia Hao
    Ko, Jen-Chung
    Yu, Chong-Jen
    RESPIROLOGY, 2018, 23 : 284 - 284
  • [50] Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
    Velez, Maria A.
    Burns, Timothy F.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S339 - S342
12345